DB16368InvestigationalProtein Based Therapies
Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for... INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum.
- Also known as
- Anti-SARS-CoV-2 equine immunoglobulin fragments F(ab')2 · INOSARS
- Code names
- Anti-SARS-CoV-2 equine immunoglobulin fragments
What you can answer from here — as of December 20, 2020
Which companies are running trials of Anti-SARS-CoV-2 equine immunoglobulin fragments, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account